Therapeutic methods employing sialylated glycoforms of soluble complement receptor 1 (SCR 1)
US5858969A · kind A · utility
52Cited by
2References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Jan 12, 1999 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are therapeutic methods employing preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms. The methods are suitable for treatment of disease involving inflammation, inappropriate complement activation, and in thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid:mannose molar ratio of .gtoreq.0.25.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.